Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 4, 2012, Pages 647-652

  Spraggs, C F ^a   Parham, L R ^b   Hunt, C M ^b   Dollery, C T ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1; HLA ANTIGEN CLASS 2; LAPATINIB; LETROZOLE; PACLITAXEL; PLACEBO; TRASTUZUMAB;

ALLELE; ARTICLE; CLINICAL ARTICLE; GENOTYPE; GILBERT DISEASE; HUMAN; HYS LAW; LIVER INJURY; LIVER TOXICITY; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS;

ALANINE TRANSAMINASE; DRUG-INDUCED LIVER INJURY; GENOTYPE; GILBERT DISEASE; GLUCURONOSYLTRANSFERASE; HLA-DQ ALPHA-CHAINS; HLA-DRB1 CHAINS; HUMANS; INCIDENCE; QUINAZOLINES;

EID: 84858800741     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.277     Document Type: Article

References (18)

1. Senior, J.R. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin. Pharmacol. Ther. 85, 331-334 (2009).
2. Aithal, G.P. et al. Case definition and phenotype standardization in druginduced liver injury. Clin. Pharmacol. Ther. 89, 806-815 (2011).
3. Bosma, P.J. et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175 (1995).
4. Hirschfield, G.M. & Alexander, G.J. Gilbert's syndrome: an overview for clinical biochemists. Ann. Clin. Biochem. 43, 340-343 (2006). (Pubitemid 44526531)
5. Danoff, T.M. et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J. 4, 49-53 (2004). (Pubitemid 38256605)
6. Singer, J.B. et al. UGT1A1 promoter polymorphism increases risk of nilotinibinduced hyperbilirubinemia. Leukemia 21, 2311-2315 (2007). (Pubitemid 350019230)
7. Lee, J.S. et al. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinaemia in patients receiving tocilizumab. Pharmacogenet. Genomics 21, 365-374 (2011).
8. Phillips, E.J. & Mallal, S.A. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 11, 973-987 (2010).
9. Spraggs, C.F. et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667-673 (2011).
10. Moy, B. et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J Clin Oncol 27 (suppl.), abstr. 1043, 15s (2009).
11. Andrade, R.J. et al.; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129, 512-521 (2005). (Pubitemid 41096639)
12. Bj?nsson, E. & Olsson, R. Outcome and prognostic markers in severe druginduced liver disease. Hepatology 42, 481-489 (2005). (Pubitemid 41061102)
13. US Food and Drug Administration. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation (2009).
14. Bj?nsson, E. Drug-induced liver injury: Hy's rule revisited. Clin. Pharmacol. Ther. 79, 521-528 (2006).
15. Spraggs, C.F. et al. Hyperbilirubinemia in lapatinib treated patients is associated with Gilbert's syndrome UGT1A1 polymorphism. Cancer Res. 69(24 suppl.), abstr. 1112 (2009).
16. Watkins, P.B. et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 34, 243-252 (2011).
17. GlaxoSmithKline. TYKERB? (lapatinib) prescribing information (2011).
18. Rockey, D.C. et al.; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 51, 2117-2126 (2010).